WO2008129971A1 - 改良された持続感染型センダイウイルスベクター - Google Patents

改良された持続感染型センダイウイルスベクター Download PDF

Info

Publication number
WO2008129971A1
WO2008129971A1 PCT/JP2008/057212 JP2008057212W WO2008129971A1 WO 2008129971 A1 WO2008129971 A1 WO 2008129971A1 JP 2008057212 W JP2008057212 W JP 2008057212W WO 2008129971 A1 WO2008129971 A1 WO 2008129971A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
virus vector
infective
sendai virus
amino acid
Prior art date
Application number
PCT/JP2008/057212
Other languages
English (en)
French (fr)
Inventor
Ken Nishimura
Hiroaki Segawa
Mahito Nakanishi
Original Assignee
National Institute Of Advanced Industrial Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Advanced Industrial Science And Technology filed Critical National Institute Of Advanced Industrial Science And Technology
Priority to US12/595,497 priority Critical patent/US9145564B2/en
Priority to JP2009510838A priority patent/JP4936482B2/ja
Publication of WO2008129971A1 publication Critical patent/WO2008129971A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18821—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

　非持続感染型センダイウイルスのＬタンパク質の１６１８番目のアミノ酸残基がバリンに置換されたアミノ酸配列をコードするように変換された遺伝子を用いて、持続感染型ウイルスベクターを作製するとともに、さらに、Ｍ、Ｆ及びＨＮ遺伝子の１種以上を欠損ないしは欠失させて、非伝播性持続感染型ウイルスベクターを作製する。これらは細胞障害性がなく、長期間持続する遺伝子発現を実現でき、安全で、有用なウイルスベクターである。
PCT/JP2008/057212 2007-04-13 2008-04-11 改良された持続感染型センダイウイルスベクター WO2008129971A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/595,497 US9145564B2 (en) 2007-04-13 2008-04-11 Persistently infective Sendai virus vector
JP2009510838A JP4936482B2 (ja) 2007-04-13 2008-04-11 改良された持続感染型センダイウイルスベクター

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007105786 2007-04-13
JP2007-105786 2007-04-13

Publications (1)

Publication Number Publication Date
WO2008129971A1 true WO2008129971A1 (ja) 2008-10-30

Family

ID=39875500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057212 WO2008129971A1 (ja) 2007-04-13 2008-04-11 改良された持続感染型センダイウイルスベクター

Country Status (3)

Country Link
US (1) US9145564B2 (ja)
JP (1) JP4936482B2 (ja)
WO (1) WO2008129971A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010018961A1 (de) * 2010-04-23 2011-10-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
EP2434012A1 (en) * 2009-05-18 2012-03-28 National Institute of Advanced Industrial Science And Technology Vector material for creating pluripotent stem cells, and pluripotent stem cell creation method using said vector material
WO2012063817A1 (ja) 2010-11-09 2012-05-18 独立行政法人産業技術総合研究所 末梢血単球由来多能性幹細胞作製方法
US9145564B2 (en) 2007-04-13 2015-09-29 National Institute Of Advanced Industrial Science And Technology Persistently infective Sendai virus vector
US9365866B2 (en) 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
WO2020209137A1 (ja) * 2019-04-09 2020-10-15 アイ ピース， インコーポレイテッド 心筋細胞の作製方法
WO2023210616A1 (ja) * 2022-04-25 2023-11-02 ときわバイオ株式会社 Ｒｎａウイルス由来のキメラエンベロープタンパク質及び該タンパク質を持つｒｎａウイルスベクター

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135831A1 (en) 2011-04-01 2012-10-04 Yale University Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair
ES2689797T3 (es) * 2011-04-28 2018-11-15 St. Jude Children's Research Vacuna de virus Sendai modificado y vector para la obtención de imágenes
US9951349B2 (en) 2011-09-27 2018-04-24 Yale University Compositions and methods for transient expression of recombinant RNA
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
CA3027960C (en) 2016-06-15 2022-06-14 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US20200392455A1 (en) * 2017-11-30 2020-12-17 I Peace, Inc. Nerve cell production method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070070A1 (fr) * 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
JP2006180780A (ja) * 2004-12-27 2006-07-13 National Institute Of Advanced Industrial & Technology 持続感染型センダイウイルスベクター
JP2006325531A (ja) * 2005-05-27 2006-12-07 National Institute Of Advanced Industrial & Technology センダイウイルス温度感受性株由来のウイルスベクター

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US20030022376A1 (en) 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US20030166252A1 (en) 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20020169306A1 (en) 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
ES2280254T3 (es) * 1999-11-02 2007-09-16 Dnavec Research Inc. Vector de virus sendai recombinante para introducir genes exogenos en el epitelio de las vias respiratorias.
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CN1633599A (zh) 2001-09-18 2005-06-29 株式会社载体研究所 检查和制造降低了粒子形成能力的(－)链rna载体的方法
US9145564B2 (en) 2007-04-13 2015-09-29 National Institute Of Advanced Industrial Science And Technology Persistently infective Sendai virus vector

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000070070A1 (fr) * 1999-05-18 2000-11-23 Dnavec Research Inc. Vecteur de virus paramyxoviridae defectueux dans un gene enveloppe
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
JP2006180780A (ja) * 2004-12-27 2006-07-13 National Institute Of Advanced Industrial & Technology 持続感染型センダイウイルスベクター
JP2006325531A (ja) * 2005-05-27 2006-12-07 National Institute Of Advanced Industrial & Technology センダイウイルス温度感受性株由来のウイルスベクター

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOTOH B. ET AL.: "Paramyxovirus accessory proteins as interferon antagonists", MICROBIOLOGY AND IMMUNOLOGY, vol. 45, no. 12, 2001, pages 787 - 800 *
KOMATSU T. ET AL.: "C and V proteins of Sendai virus target signaling pathways leading to IRF-3 activation for the negative regulation of interferon-beta production", VIROLOGY, vol. 325, 2004, pages 137 - 148, XP004518156, DOI: doi:10.1016/j.virol.2004.04.025 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145564B2 (en) 2007-04-13 2015-09-29 National Institute Of Advanced Industrial Science And Technology Persistently infective Sendai virus vector
EP2434012A1 (en) * 2009-05-18 2012-03-28 National Institute of Advanced Industrial Science And Technology Vector material for creating pluripotent stem cells, and pluripotent stem cell creation method using said vector material
EP2434012A4 (en) * 2009-05-18 2013-11-06 Nat Inst Of Advanced Ind Scien VECTOR MATERIAL FOR GENERATING PLURIPOTENTAL STEM CELLS AND METHOD FOR GENERATING PLURIPOTENTAL STEM CELLS THROUGH THE VECTOR MATERIAL
US9365866B2 (en) 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
DE102010018961A1 (de) * 2010-04-23 2011-10-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
DE102010018961B4 (de) * 2010-04-23 2012-09-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen
WO2012063817A1 (ja) 2010-11-09 2012-05-18 独立行政法人産業技術総合研究所 末梢血単球由来多能性幹細胞作製方法
WO2020209137A1 (ja) * 2019-04-09 2020-10-15 アイ ピース， インコーポレイテッド 心筋細胞の作製方法
WO2023210616A1 (ja) * 2022-04-25 2023-11-02 ときわバイオ株式会社 Ｒｎａウイルス由来のキメラエンベロープタンパク質及び該タンパク質を持つｒｎａウイルスベクター

Also Published As

Publication number Publication date
US20100196993A1 (en) 2010-08-05
JP4936482B2 (ja) 2012-05-23
JPWO2008129971A1 (ja) 2010-07-22
US9145564B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
WO2008129971A1 (ja) 改良された持続感染型センダイウイルスベクター
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2005042728A3 (en) Immortalized avian cell lines for virus production
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2007081974A3 (en) Viral hepatitis treatment
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
EP2351843A3 (en) Rabies virus vector systems and compositions and methods thereof
TNSN08064A1 (en) Albumin fusion proteins
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
WO2006078645A3 (en) Heterologous polypeptide expression using low multiplicity of infection of viruses
EP2434020A3 (en) Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
WO2009099877A3 (en) Closterovirus vectors and methods
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
WO2010042749A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2010042751A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2010042755A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2014068409A3 (en) Use of a cement accelerator and electric arc furnace dust in cement
PH12020552252A1 (en) Influenza virus hemagglutinin mutants
WO2013036622A3 (en) Antiviral peptides effective against hepatitis c virus
WO2010008576A3 (en) Idna vaccines and methods for using the same
WO2012173344A3 (ko) Ｃｓｐ－ｂ ５'-ｓａｒ 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법
HK1167431A1 (en) Nucleic acid derived from hepatitis c virus and expression vector, transformed cell, and hepatitis c virus particles each prepared by using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751838

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009510838

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12595497

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08751838

Country of ref document: EP

Kind code of ref document: A1